Nanosonics Limited (ASX:NAN): What Do FY2026 Results Mean for CORIS Commercialisation?

Aditi Sarkar

02 November 2026 06:10 PM AEDT

Nanosonics Limited (ASX:NAN): What Do FY2026 Results Mean for CORIS Commercialisation?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY2026 Revenue reached AUD 203.9 million, while EBIT was AUD 16.0 million.
The trophon installed base expanded to 39,230 devices in FY2026.
CORIS commercial launch and associated spending are key FY2027 monitorables.

Nanosonics (ASX:NAN) develops and commercialises infection prevention technologies used in healthcare settings, including its trophon ultrasound probe disinfection platform and the CORIS endoscope reprocessing system. Shares closed at AUD 2.935 on 2 November 2026. In its FY2026 disclosures, the company reported continued trophon placements and progress towards commercial release of CORIS, with planned additional spending on the newer system. Its financial profile therefore combines sales from an established product range with Investment in a product still progressing through launch stages.

FY2026 financial performance

For the year ended 30 June 2026, Nanosonics (ASX:NAN) reported revenue of AUD 203.9 million, an increase of approximately 3% year on year. At constant currency, revenue was AUD 211.5 million, reflecting exchange-rate effects on reported growth. Earnings before interest and tax were AUD 16.0 million, down 10% on the previous corresponding period. The company separately reported trophon-only EBIT of AUD 50.6 million, a 5% increase, distinguishing its established Business from investment in newer platforms. The distinction matters because expenditure on CORIS affects group profitability before material commercial revenue is established.

trophon operations and CORIS

During FY2026, total trophon placements rose 9% to 4,230 units, and the cumulative installed base reached 39,230 devices. Recurring Revenue was AUD 149.2 million, comprising consumables, service, repairs and spare parts. Nanosonics (ASX:NAN) reported progress with next-generation trophon products and upgrades in North America. For CORIS, controlled market releases were underway across several markets. The company planned a commercial launch in the United Kingdom, Ireland and Australia in the first half of FY2027, with a United States launch to follow. Planned dates are operational objectives rather than evidence of completed launches.

Cash resources and forward spending

Nanosonics (ASX:NAN) finished June 2026 with AUD 155.2 million in cash and cash equivalents and reported no debt. Its cash movements included a AUD 20 million share buyback, alongside investment in inventory and development activity. FY2027 constant-currency guidance indicated revenue of AUD 220 million to AUD 228 million and operating expenses of AUD 156 million to AUD 163 million. Management expects a step-up in spending to support CORIS commercialisation, while initial CORIS revenue was expected in the low single-digit millions. Guidance remains subject to operating conditions, timing and foreign-exchange assumptions.

Business-specific risks and outlook

The business remains exposed to healthcare procurement cycles, equipment adoption rates, Manufacturing reliability, tariffs, freight costs and currency movements. Nanosonics (ASX:NAN) flagged potential gross-margin moderation from tariffs and freight during FY2027. CORIS involves launch execution, clinician adoption, distribution and continuing regulatory requirements, and related expenditure may precede sales. The established trophon Franchise supplies a revenue base, but its installed-base expansion and service Demand need ongoing monitoring. Investors assessing disclosed results can distinguish realised financial performance from management's targets for future commercial activity.

Key Insights

Nanosonics Limited (ASX:NAN) provides an example of how completed FY2026 results and 2026 operating developments must be read together. Revenue, profit, cash generation and any development or restructuring expenditure describe different dimensions of financial performance. The disclosed figures should be assessed alongside execution milestones, the scope of regulatory approvals and identified business risks. The closing price on 2 November 2026 is a dated market observation, not a measure of future operating results.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.